

Roy S Herbst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11983378/publications.pdf>

Version: 2024-02-01

264
papers

58,037
citations

3116

95
h-index

1238

233
g-index

273
all docs

273
docs citations

273
times ranked

50177
citing authors

#	ARTICLE	IF	CITATIONS
1	EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. <i>Clinical Lung Cancer</i> , 2022, 23, 60-71.	1.1	5
2	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 423-433.	0.5	89
3	Development of an immunohistochemical assay for Siglec-15. <i>Laboratory Investigation</i> , 2022, 102, 771-778.	1.7	8
4	Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. <i>Laboratory Investigation</i> , 2022, 102, 1143-1149.	1.7	5
5	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
6	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Nonâ€“Small-Cell Lung Cancer Previously Treated With Immunotherapyâ€“Lung-MAP S1800A. <i>Journal of Clinical Oncology</i> , 2022, 40, 2295-2307.	0.8	84
7	When immunotherapy meets surgery in non-small cell lung cancer. <i>Cancer Cell</i> , 2022, 40, 603-605.	7.7	7
8	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. , 2022, 10, e004440.		49
9	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
10	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 289-298.	0.5	35
11	SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). <i>Clinical Lung Cancer</i> , 2021, 22, 178-186.	1.1	6
12	A Phase II Study of Telisotuzumab Vedotin in Patients With câ€“MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). <i>Clinical Lung Cancer</i> , 2021, 22, 170-177.	1.1	41
13	A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 1700-1715.	7.7	86
14	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). <i>JCO Oncology Practice</i> , 2021, 17, e1821-e1829.	1.4	4
15	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repairâ€“Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. <i>Clinical Lung Cancer</i> , 2021, 22, 187-194.e1.	1.1	18
16	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 625-644.	12.5	148
17	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1â€“Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1872-1882.	0.5	85
18	Toward personalized treatment approaches for non-small-cell lung cancer. <i>Nature Medicine</i> , 2021, 27, 1345-1356.	15.2	338

#	ARTICLE	IF	CITATIONS
19	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)., 2021, 9, e002973.		26
20	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1â€“Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. JTO Clinical and Research Reports, 2021, 2, 100205.	0.6	32
21	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer. JAMA Oncology, 2021, 7, 1368.	3.4	57
22	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1â€“Positive Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1718-1732.	0.5	141
23	Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. Clinical Cancer Research, 2020, 26, 970-977.	3.2	200
24	Frontline immunotherapy for NSCLC â€” the tale of the tail. Nature Reviews Clinical Oncology, 2020, 17, 73-74.	12.5	35
25	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq1 1 0.784314 rgBT /Overlook	5.1	68
26	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers, 2020, 12, 2985.	1.7	21
27	Osimertinib in Resected EGFR-Mutated Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2020, 383, 1711-1723.	13.9	1,042
28	PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research, 2020, 26, 4186-4197.	3.2	44
29	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncology, The, 2020, 21, 655-663.	5.1	335
30	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology, 2020, 15, 914-947.	0.5	119
31	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1â€“Positive, Advanced Nonâ€“Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology, 2020, 38, 1580-1590.	0.8	189
32	Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Nonâ€“Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling. Clinical Cancer Research, 2020, 26, 4360-4368.	3.2	73
33	Practical Considerations Relating to Routine Clinical Biomarker Testing for Nonâ€“small Cell Lung Cancer: Focus on Testing for RET Fusions. Frontiers in Medicine, 2020, 7, 562480.	1.2	6
34	Atezolizumab for First-Line Treatment of PD-L1â€“Selected Patients with NSCLC. New England Journal of Medicine, 2020, 383, 1328-1339.	13.9	959
35	Introduction by the Guest Editors. Cancer Journal (Sudbury, Mass), 2020, 26, 471-472.	1.0	0
36	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncology, The, 2019, 20, 1109-1123.	5.1	193

#	ARTICLE	IF	CITATIONS
37	SWOG S1400C (NCT02154490)â€”A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alterationâ€”Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Journal of Thoracic Oncology, 2019, 14, 1853-1859.	0.5	58
38	Small molecule combats cancer-causing KRAS protein at last. Nature, 2019, 575, 294-295.	13.7	19
39	Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Nonâ€”Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 2084-2096.	0.5	48
40	SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathwayâ€”Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Journal of Thoracic Oncology, 2019, 14, 1847-1852.	0.5	62
41	SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). Journal of Thoracic Oncology, 2019, 14, 1839-1846.	0.5	53
42	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1046-1060.	0.5	52
43	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1â€”Expressing NSCLC. Journal of Thoracic Oncology, 2019, 14, 793-801.	0.5	50
44	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Nonâ€”Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clinical Cancer Research, 2019, 25, 4663-4673.	3.2	210
45	Immunotherapy in Nonâ€”Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research, 2019, 25, 4592-4602.	3.2	447
46	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine, 2019, 25, 656-666.	15.2	461
47	Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). , 2019, 7, 65.		108
48	Challenges and approaches to implementing master/basket trials in oncology. Blood Advances, 2019, 3, 2237-2243.	2.5	11
49	Treatment of Advanced Nonâ€”Small Cell Lung Cancer in 2018. JAMA Oncology, 2018, 4, 569.	3.4	82
50	The biology and management of non-small cell lung cancer. Nature, 2018, 553, 446-454.	13.7	2,877
51	Immune Checkpoint Inhibition in Lung Cancer. , 2018, , 333-344.		0
52	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Nonâ€”Small Cell Lung Carcinoma. JAMA Oncology, 2018, 4, 210.	3.4	437
53	Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clinical Cancer Research, 2018, 24, 1872-1880.	3.2	319
54	ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clinical Lung Cancer, 2018, 19, e533-e536.	1.1	80

#	ARTICLE	IF	CITATIONS
55	Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Nonâ€“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 831-839.	0.5	94
56	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1562-1573.	3.2	150
57	Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 101-114.	5.1	62
58	Management of Advanced Nonâ€“Small Cell Lung Cancer. , 2018, , 99-115.		1
59	Should chemotherapy plus immune checkpoint inhibition be the standard frontâ€“line therapy for patients with metastatic nonâ€“small cell lung cancer?. <i>Cancer</i> , 2018, 124, 4592-4596.	2.0	7
60	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2018, 39, 624-631.	2.9	153
61	Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Nonâ€“Small Cell Lung Cancer in the Community Oncology Setting. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 469.	3.8	110
62	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , 2018, 101, 201-209.	1.3	41
63	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
64	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). <i>Oncologist</i> , 2018, 23, 1407-e136.	1.9	127
65	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i>-altered non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33995-34008.	0.8	9
66	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBIâ€“Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1661-1670.	2.5	59
67	Immunotherapy in Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 131-141.	0.9	31
68	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. <i>Clinical Cancer Research</i> , 2017, 23, 5202-5209.	3.2	99
69	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5489-5501.	3.2	55
70	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 1420-1435.	7.7	507
71	JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Nonâ€“Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2234-2245.	1.9	72
72	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Î²-blockers. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	96

#	ARTICLE	IF	CITATIONS
73	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. , 2017, 5, .		11
74	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research, 2017, 23, 370-378.	3.2	150
75	A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.. Journal of Clinical Oncology, 2017, 35, 9054-9054.	0.8	13
76	Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.. Journal of Clinical Oncology, 2017, 35, 9055-9055.	0.8	14
77	A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.. Journal of Clinical Oncology, 2017, 35, 9056-9056.	0.8	11
78	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GE) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).. Journal of Clinical Oncology, 2017, 35, 102-102.	0.8	20
79	A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.. Journal of Clinical Oncology, 2017, 35, 349-349.	0.8	19
80	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non- Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 3638-3647.	0.8	140
81	Diminished but not dead: chemotherapy for the treatment of NSCLC. Lancet Oncology, The, 2016, 17, 1464-1465.	5.1	21
82	Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1430-1468.	2.3	122
83	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 976-983.	5.1	846
84	Nivolumab and Pembrolizumab for Non- Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 3713-3717.	3.2	62
85	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, The, 2016, 387, 1540-1550.	6.3	5,456
86	Scientific Advances in Lung Cancer 2015. Journal of Thoracic Oncology, 2016, 11, 613-638.	0.5	231
87	Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy, 2016, 8, 279-298.	1.0	56
88	Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research. Clinical Cancer Research, 2016, 22, 1907-1913.	3.2	64
89	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research, 2016, 22, 2102-2104.	3.2	31
90	Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development. Statistics in Biosciences, 2016, 8, 99-128.	0.6	22

#	ARTICLE	IF	CITATIONS
91	A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. PLoS ONE, 2015, 10, e0122628.	1.1	20
92	Lung Cancer in the Era of Precision Medicine. Clinical Cancer Research, 2015, 21, 2213-2220.	3.2	148
93	Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Clinical Cancer Research, 2015, 21, 514-525.	3.2	66
94	Electronic Nicotine Delivery Systems: A Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology. Journal of Clinical Oncology, 2015, 33, 952-963.	0.8	102
95	Lung Master Protocol (Lung-MAP)â€”A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clinical Cancer Research, 2015, 21, 1514-1524.	3.2	205
96	E2F8 as a Novel Therapeutic Target for Lung Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	80
97	EGFR tyrosine kinase inhibitors in squamous cell lung cancer. Lancet Oncology, The, 2015, 16, 872-873.	5.1	8
98	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i>-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	7.7	696
99	Molecularly Targeted Therapies in Nonâ€”Small-Cell Lung Cancer Annual Update 2014. Journal of Thoracic Oncology, 2015, 10, S1-S63.	0.5	119
100	Objective Measurement and Clinical Significance of TILs in Nonâ€”Small Cell Lung Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	325
101	A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer, 2015, 15, 171.	1.1	51
102	Phase I Trials Today. , 2015, , 661-676.e2.		0
103	Lung-MAPâ€”framework, overview, and design principles. Chinese Clinical Oncology, 2015, 4, 36.	0.4	24
104	AACR Celebrates 50 Years of Tobacco Research and Policy. Clinical Cancer Research, 2014, 20, 1709-1718.	3.2	0
105	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515, 563-567.	13.7	4,342
106	B7-H1/PD-1 Blockade Therapy in Nonâ€”Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2014, 20, 281-289.	1.0	63
107	â€œCompanion Diagnosticsâ€”Has Their Time Come and Gone?. Clinical Cancer Research, 2014, 20, 4422-4424.	3.2	18
108	â€œQuitting Smoking Will Benefit Your Healthâ€”The Evolution of Clinician Messaging to Encourage Tobacco Cessation. Clinical Cancer Research, 2014, 20, 301-309.	3.2	67

#	ARTICLE	IF	CITATIONS
109	Angiogenesis inhibition and lung-cancer therapy. <i>Lancet Oncology</i> , The, 2014, 15, 124-125.	5.1	6
110	Vandetanib and Indwelling Pleural Catheter for Non-Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion. <i>Clinical Lung Cancer</i> , 2014, 15, 379-386.	1.1	13
111	Programmed death ligand-1 expression in non-small cell lung cancer. <i>Laboratory Investigation</i> , 2014, 94, 107-116.	1.7	697
112	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1-14.	1.5	38
113	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 1277-1280.	0.8	354
114	New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs. <i>Clinical Cancer Research</i> , 2014, 20, 4425-4435.	3.2	33
115	A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3921-3930.	3.2	79
116	A step towards treating KRAS-mutant NSCLC. <i>Lancet Oncology</i> , The, 2013, 14, 3-5.	5.1	6
117	Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. <i>Cancer Cytopathology</i> , 2013, 121, 500-507.	1.4	60
118	An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 279-290.	3.2	848
119	Phase IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. <i>European Journal of Cancer</i> , 2013, 49, 1815-1824.	1.3	18
120	Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement. <i>Clinical Cancer Research</i> , 2013, 19, 1941-1948.	3.2	182
121	CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma. <i>Cancer Research</i> , 2013, 73, 571-582.	0.4	138
122	Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial. <i>Clinical Cancer Research</i> , 2013, 19, 6967-6975.	3.2	57
123	Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 140-146.	0.5	25
124	Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer: SWOG S0536. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1519-1528.	0.5	22
125	BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8118-TPS8118.	0.8	4
126	Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials. <i>Clinical Cancer Research</i> , 2012, 18, 638-644.	3.2	41

#	ARTICLE	IF	CITATIONS
127	Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. <i>Journal of the National Cancer Institute</i> , 2012, 104, 228-239.	3.0	424
128	Tobacco Assessment in Actively Accruing National Cancer Institute Cooperative Group Program Clinical Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 2869-2875.	0.8	48
129	Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819. <i>Clinical Cancer Research</i> , 2012, 18, 4004-4012.	3.2	45
130	Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis. <i>Clinical Cancer Research</i> , 2012, 18, 1641-1654.	3.2	51
131	Targeting Vascular Endothelial Growth Factor in Patients With Squamous Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1137-1139.	0.8	6
132	Multitargeted Tyrosine Kinase Inhibitors in Unselected Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC): Impressions From MONET (the Motesanib NSCLC Efficacy and Tolerability Study). <i>Journal of Clinical Oncology</i> , 2012, 30, 2805-2808.	0.8	3
133	Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 Years. <i>Clinical Lung Cancer</i> , 2012, 13, 115-122.	1.1	93
134	The BATTLE Trial: Personalizing Therapy for Lung Cancer. <i>Cancer Discovery</i> , 2011, 1, 44-53.	7.7	778
135	Methodological and practical challenges for personalized cancer therapies. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 135-141.	12.5	159
136	Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , 2011, 377, 1846-1854.	6.3	370
137	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2011, 121, 1313-1328.	3.9	141
138	Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). <i>Investigational New Drugs</i> , 2011, 29, 499-505.	1.2	18
139	Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324. <i>Journal of Clinical Oncology</i> , 2011, 29, 2312-2318.	0.8	161
140	Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non-Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. <i>Cancer Research</i> , 2011, 71, 5512-5521.	0.4	55
141	A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1054-1059.	0.5	84
142	Treatment with HIF-1 α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice. <i>Journal of Thoracic Oncology</i> , 2010, 5, 940-949.	0.5	63
143	Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2839-2846.	0.8	394
144	Chemoradiotherapy With or Without AE-941 in Stage III Non-Small Cell Lung Cancer: A Randomized Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 859-865.	3.0	64

#	ARTICLE	IF	CITATIONS
145	Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Study S0342. <i>Journal of Clinical Oncology</i> , 2010, 28, 4747-4754.	0.8	66
146	Tobacco and Cancer: An American Association for Cancer Research Policy Statement. <i>Cancer Research</i> , 2010, 70, 3419-3430.	0.4	51
147	A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 5883-5891.	3.2	121
148	VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. <i>Lung Cancer</i> , 2010, 69, 337-340.	0.9	50
149	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2010, 11, 619-626.	5.1	407
150	Integration of Molecular Profiling into the Lung Cancer Clinic. <i>Clinical Cancer Research</i> , 2009, 15, 5317-5322.	3.2	82
151	Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3600-3609.	3.2	90
152	Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 3557-3565.	0.8	258
153	Beyond Doublet Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy. <i>Clinical Lung Cancer</i> , 2009, 10, 20-27.	1.1	17
154	Evolving Treatment Algorithms for Advanced Non-Small-Cell Lung Cancer: 2009 Looking Toward 2012. <i>Clinical Lung Cancer</i> , 2009, 10, 392-394.	1.1	22
155	Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2009, 10, 13-19.	1.1	1
156	A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2009, 115, 1713-1722.	2.0	35
157	Epidermal growth factor receptor expression analysis in chemotherapy-naïve patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 467-476.	1.2	9
158	Patient selection criteria and the FLEX Study. <i>Lancet</i> , The, 2009, 373, 1497-1498.	6.3	4
159	Tumor Blood Flow Measured by Perfusion Computed Tomography and 15O-Labeled Water Positron Emission Tomography. <i>Journal of Computer Assisted Tomography</i> , 2009, 33, 460-465.	0.5	22
160	Multitargeted Inhibitors in Lung Cancer: New Clinical Data. <i>Clinical Lung Cancer</i> , 2008, 9, S92-S99.	1.1	10
161	Lung Cancer. <i>New England Journal of Medicine</i> , 2008, 359, 1367-1380.	13.9	2,271
162	Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib. <i>Journal of Clinical Oncology</i> , 2008, 26, 1472-1478.	0.8	284

#	ARTICLE	IF	CITATIONS
163	Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5407-5415.	0.8	214
164	Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. <i>Oncologist</i> , 2008, 13, 1166-1176.	1.9	46
165	Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass ¹⁸ F-FDG Uptake: A Comparison with ¹⁵ O-Labeled Water-Measured Blood Flow. <i>Journal of Nuclear Medicine</i> , 2008, 49, 517-523.	2.8	90
166	Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1135-1141.	0.8	66
167	Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non-Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 3351-3357.	0.8	278
168	Bayesian adaptive design for targeted therapy development in lung cancer – a step toward personalized medicine. <i>Clinical Trials</i> , 2008, 5, 181-193.	0.7	199
169	Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 351-357.	0.5	64
170	Advances in the Treatment of Metastatic Non-Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. <i>Clinical Pulmonary Medicine</i> , 2008, 15, 352-358.	0.3	0
171	To kill a tumor cell: the potential of proapoptotic receptor agonists. <i>Journal of Clinical Investigation</i> , 2008, 118, 1979-1990.	3.9	282
172	Phase 1 Trials Today. , 2008, , 553-570.		0
173	Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 471-483.	1.9	84
174	Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 6175-6181.	3.2	96
175	Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 2369-2376.	0.8	192
176	Enzastaurin, a Protein Kinase C α -Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 4641s-4646s.	3.2	34
177	KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2890-2896.	3.2	597
178	Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 239-249.	1.9	131
179	Expression of epidermal growth factor (EGF)/transforming growth factor- β by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2652-2663.	1.9	40
180	Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4270-4277.	0.8	286

#	ARTICLE	IF	CITATIONS
181	Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4743-4750.	0.8	386
182	Molecular Signatures of Lung Cancer – Toward Personalized Therapy. <i>New England Journal of Medicine</i> , 2007, 356, 76-78.	13.9	71
183	Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 870-878.	0.4	44
184	Targeted Therapy Against VEGFR and EGFR With ZD6474 Enhances the Therapeutic Efficacy of Irradiation in an Orthotopic Model of Human Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1534-1543.	0.4	58
185	2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006. <i>Clinical Lung Cancer</i> , 2007, 8, 234-241.	1.1	0
186	Phase I participants' views of quality of life and trial participation burdens. <i>Supportive Care in Cancer</i> , 2007, 15, 885-890.	1.0	20
187	PD3-3-4: Vandetanib in advanced NSCLC: an ongoing clinical evaluation program. <i>Journal of Thoracic Oncology</i> , 2007, 2, S467-S468.	0.5	2
188	Therapeutic options to target angiogenesis in human malignancies. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 635-650.	1.0	68
189	Use of Novel Second-Line Targeted Therapies in Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2006, 33, 9-16.	0.8	27
190	Asian Ethnicity as a Predictor of Response in Patients with Non-Small-Cell Lung Cancer Treated with Gefitinib on an Expanded Access Program. <i>Clinical Lung Cancer</i> , 2006, 7, 326-331.	1.1	27
191	Toxicities of Antiangiogenic Therapy in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2006, 8, S23-S30.	1.1	46
192	Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening – A Report From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2006, 24, 190-205.	0.8	108
193	Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C- β Inhibitor. <i>Clinical Cancer Research</i> , 2006, 12, 3408-3415.	3.2	48
194	Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy. <i>Seminars in Oncology</i> , 2005, 32, 315-328.	0.8	43
195	Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 2946-2954.	0.8	107
196	Tumor Cavitation in Stage I Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome. <i>Radiology</i> , 2005, 237, 342-347.	3.6	84
197	Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2005, 23, 5578-5587.	0.8	382
198	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5464-5473.	0.8	271

#	ARTICLE	IF	CITATIONS
199	Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2544-2555.	0.8	545
200	Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results. <i>Journal of Clinical Oncology</i> , 2005, 23, 5474-5483.	0.8	470
201	Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 9089-9096.	0.8	145
202	Molecular targeted therapy for lung cancer. <i>Lancet, The</i> , 2005, 366, 1507-1508.	6.3	8
203	Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 8081-8092.	0.8	608
204	Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications. <i>Journal of Clinical Oncology</i> , 2005, 23, 3243-3256.	0.8	244
205	Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non-Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib. <i>Journal of Clinical Oncology</i> , 2005, 23, 5900-5909.	0.8	1,405
206	TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5892-5899.	0.8	1,414
207	Angiogenesis pathway inhibitors. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 225-245.	0.5	2
208	Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. <i>Clinical Cancer Research</i> , 2005, 11, 678-89.	3.2	27
209	Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 136-143.	3.2	143
210	Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 33-42.	3.2	38
211	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 8613-8619.	3.2	17
212	Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial—INTACT 2. <i>Journal of Clinical Oncology</i> , 2004, 22, 785-794.	0.8	1,669
213	Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2184-2191.	0.8	1,917
214	Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab?. <i>Oncologist</i> , 2004, 9, 19-26.	1.9	63
215	Gefitinib — a novel targeted approach to treating cancer. <i>Nature Reviews Cancer</i> , 2004, 4, 956-965.	12.8	340
216	Overview of the Current Status of Human Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. <i>Clinical Lung Cancer</i> , 2004, 6, S7-S19.	1.1	31

#	ARTICLE	IF	CITATIONS
217	Review of epidermal growth factor receptor biology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, S21-S26.	0.4	1,094
218	Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 308-314.	1.1	37
219	Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. <i>Cancer</i> , 2004, 101, 1733-1744.	2.0	9
220	Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. <i>Lung Cancer</i> , 2004, 44, 99-110.	0.9	122
221	Pemetrexed in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Review of the Clinical Data. <i>Clinical Lung Cancer</i> , 2004, 5, S67-S74.	1.1	8
222	Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial—INTACT 1. <i>Journal of Clinical Oncology</i> , 2004, 22, 777-784.	0.8	1,663
223	Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4258s-4262s.	3.2	103
224	Imaging in drug development. <i>Clinical Advances in Hematology and Oncology</i> , 2004, 2, 268-9.	0.3	5
225	EGFR inhibition in NSCLC: the emerging role of cetuximab. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2 Suppl 2, S41-51.	2.3	0
226	Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. <i>Seminars in Oncology</i> , 2003, 30, 30-38.	0.8	42
227	Integration of Targeted Therapies in Gemcitabine Chemotherapy Regimens. <i>Clinical Lung Cancer</i> , 2003, 4, 217-223.	1.1	2
228	Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management. <i>Clinical Lung Cancer</i> , 2003, 4, 366-369.	1.1	106
229	The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. <i>Seminars in Oncology</i> , 2003, 30, 113-123.	0.8	13
230	Erlotinib (Tarceva): An update on the clinical trial program. <i>Seminars in Oncology</i> , 2003, 30, 34-46.	0.8	80
231	Mode of action of docetaxel—a basis for combination with novel anticancer agents. <i>Cancer Treatment Reviews</i> , 2003, 29, 407-415.	3.4	192
232	Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2149.	3.8	2,360
233	Interobserver and Intraobserver Variability in Measurement of Non-Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor Response. <i>Journal of Clinical Oncology</i> , 2003, 21, 2574-2582.	0.8	435
234	Antiangiogenic Tumor Therapy. <i>BioTechniques</i> , 2003, 34, 1048-1063.	0.8	12

#	ARTICLE	IF	CITATIONS
235	The Role of Growth Factor Signaling in Malignancy. , 2003, 115, 19-72.		13
236	A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 4108-15.	3.2	38
237	Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. <i>Clinical Cancer Research</i> , 2003, 9, 5532-9.	3.2	133
238	Targeting the epidermal growth factor receptor in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5813-24.	3.2	103
239	Gefitinib: current and future status in cancer therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 466-72.	0.3	15
240	ZD1839: targeting the epidermal growth factor receptor in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 837-849.	1.9	56
241	Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin. <i>Journal of Clinical Oncology</i> , 2002, 20, 3804-3814.	0.8	187
242	Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non-Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 3815-3825.	0.8	558
243	Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2002, 20, 3792-3803.	0.8	280
244	Study of the Media's Potential Influence on Prospective Research Participants' Understanding of and Motivations for Participation in a High-Profile Phase I Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 3785-3791.	0.8	59
245	Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined With Paclitaxel in Patients With Solid Tumors: Evidence for Activity in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 4440-4447.	0.8	98
246	ZD1839 (Iressa,®) in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2002, 7, 9-15.	1.9	300
247	Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. <i>Lung Cancer</i> , 2002, 37, 17-27.	0.9	27
248	Targeted Therapy Using Novel Agents in the Treatment of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2002, 3, S30-S38.	1.1	19
249	Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. <i>Seminars in Oncology</i> , 2002, 29, 27-36.	0.8	202
250	Angiogenesis inhibitors in clinical development for lung cancer. <i>Seminars in Oncology</i> , 2002, 29, 66-77.	0.8	48
251	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. <i>Cancer</i> , 2002, 94, 1593-1611.	2.0	441
252	The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2002, 95, 340-353.	2.0	34

#	ARTICLE	IF	CITATIONS
253	Angiogenesis inhibitors in lung cancer. <i>Current Oncology Reports</i> , 2002, 4, 325-333.	1.8	11
254	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. <i>Seminars in Oncology</i> , 2002, 29, 18-30.	0.8	70
255	Targeted therapy in non-small-cell lung cancer. <i>Oncology</i> , 2002, 16, 19-24.	0.4	18
256	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 719-732.	1.4	98
257	Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 151-159.	1.1	28
258	Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin. <i>Current Oncology Reports</i> , 2001, 3, 131-140.	1.8	44
259	Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2001, 92, 2364-2373.	2.0	46
260	ZD1839 (Iressa,®) In Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2001, 3, 27-32.	1.1	13
261	Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells. <i>American Journal of Pathology</i> , 2000, 157, 1893-1903.	1.9	143
262	Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 497-504.	1.1	65
263	CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER. <i>Hematology/Oncology Clinics of North America</i> , 1997, 11, 473-517.	0.9	15
264	Tyrosine-kinase inhibitors in oncology. , 0, , 872-883.		0